Dr. Lunin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1970 Golf St
Sarasota, FL 34236Phone+1 941-957-1000Fax+1 941-951-2117
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
Duke University HospitalResidency, Internal Medicine, 1995 - 1998
Duke University School of MedicineClass of 1995
washington universityBS, Biology, Cum Laude, 1987 - 1991
Certifications & Licensure
FL State Medical License 2001 - 2025
TX State Medical License 2000 - 2003
NC State Medical License 1996 - 2001- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Sarasota Magazine: Top Doctors Castle Connolly, 2014
- Gulfshore Life Magazine: Top Doctors Castle Connolly, 2012-2013
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2011-2014
Clinical Trials
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
- A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
Publications & Presentations
PubMed
- 246 citationsThe phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLLIan W. Flinn, Peter Hillmen, Marco Montillo, Zsolt Nagy, Árpád Illés
Blood. 2018-12-06 - 180 citationsDYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.Ian W. Flinn, Carole B. Miller, Kirit M. Ardeshna, Scott A. Tetreault, Sarit Assouline
Journal of Clinical Oncology. 2019-02-11 - 29 citationsUblituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, o...Jeff P. Sharman, Danielle M. Brander, Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster
The Lancet. Haematology. 2021-04-01
Journal Articles
- The Phase 3 DUO Trial: Duvelisib Versus Ofatumumab in Relapsed and Refractory CLL/SLLMatthew S Davids, Ian W Flinn, Craig A Portell, Nicole Lamanna, Scott Lunin, Amanda F Cashen, Blood
Abstracts/Posters
- Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Te...Scott D. Lunin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best...Scott D. Lunin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
